Evidence map›Paper›PMID 28560600›Full record

Trial reportAnnals of surgical oncology2017

Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study.

C Bisschop, T H van Dijk, J C Beukema, R L H Jansen, H Gelderblom, K P de Jong, H J T Rutten, C J H van de Velde, T Wiggers, K Havenga and 1 more

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Patient- and physician-reported radiation-induced toxicity of short-course radiotherapy with a prolonged interval to surgery for rectal cancer.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2023
    Article
  11. Review
  12. Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022
    Article
  13. Local Therapies in Advanced Colorectal Cancer.Hematology/oncology clinics of North America · 2022
    Review
  14. Article
  15. Short-course radiotherapy in stage IV rectal cancer with resectable disease.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  16. Article
  17. Neoadjuvant Pelvic Radiotherapy in the Management of Rectal Cancer with Synchronous Liver Metastases: Is It Worth It?Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021
    Review
  18. Review
  19. Planned Short-Course Radiation (scRT) is Superior to Upfront Concurrent Chemoradiation (CCRT) in Treating Metastatic Rectal Cancer.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020
    Article
  20. Comprehensive review of targeted therapy for colorectal cancer.Signal transduction and targeted therapy · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

C BisschopDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
T H van DijkDepartment of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
J C BeukemaDepartment of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
R L H JansenDepartment of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands.
H GelderblomDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
K P de JongDepartment of Hepato-Pancreato-Biliary Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
H J T RuttenDepartment of Surgery, Catharina Hospital, Eindhoven, The Netherlands.
C J H van de VeldeDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
T WiggersDepartment of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
K HavengaDepartment of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
G A P HospersDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. g.a.p.hospers@umcg.nl.
University of Groningen · NLUniversity Medical Center Groningen · NLLeiden University Medical Center · NLCatharina Ziekenhuis · NLMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn a Dutch phase II trial conducted between 2006 and 2010, short-course radiotherapy followed by systemic therapy with capecitabine, oxaliplatin, and bevacizumab as neoadjuvant treatment and subsequent radical surgical treatment of primary tumor and metastatic sites was evaluated. In this study, we report the long-term results after a minimum follow-up of 6 years.

methodsPatients with histologically confirmed rectal adenocarcinoma with potentially resectable or ablatable metastases in liver or lungs were eligible. Follow-up data were collected for all patients enrolled in the trial. Overall and recurrence-free survival were calculated using the Kaplan-Meier method.

resultsFollow-up data were available for all 50 patients. After a median follow-up time of 8.1 years (range 6.0-9.8), 16 patients (32.0%) were still alive and 14 (28%) were disease-free. The median overall survival was 3.8 years (range 0.5-9.4). From the 36 patients who received radical treatment, two (5.6%) had a local recurrence and 29 (80.6%) had a distant recurrence.

conclusionsLong-term survival can be achieved in patients with primary metastatic rectal cancer after neoadjuvant radio- and chemotherapy. Despite a high number of recurrences, 32% of patients were alive after a median follow-up time of 8.1 years.

Indexed as

AdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCapecitabineChemoradiotherapy, AdjuvantDisease-Free SurvivalFemaleHumansLiver NeoplasmsLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingBevacizumabCapecitabineOrganoplatinum CompoundsOxaliplatin

Identifiers

PMID28560600
PMCPMC5539276
OpenAlexW2619503615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.